Graft vs Host Disease × Busulfan × Clear all
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT03128359 2024-01-09

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

City of Hope Medical Center

Phase 2 Completed
38 enrolled 11 charts
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT00003270 2019-12-13

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Roswell Park Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
NCT00290628 2017-11-29

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
43 enrolled
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00555048 2017-05-24

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
1 enrolled 5 charts
NCT00003414 2015-07-20

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 3 Completed
50 enrolled
NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn
NCT00014469 2013-03-07

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
NCT00005641 2012-12-11

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
NCT00253552 2012-05-28

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

OHSU Knight Cancer Institute

Phase NA Terminated
4 enrolled
NCT00003335 2012-03-15

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
44 enrolled
NCT00003661 2011-03-07

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Roswell Park Cancer Institute

Phase 2 Completed
3 enrolled
NCT00054340 2010-05-14

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00346359 2010-05-14

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
40 enrolled
NCT00740467 2010-01-28

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled